An Oral Drug Eased Hereditary Angioedema Attacks in 1.28 Hours
A Lancet phase 3 trial found an oral drug eased hereditary angioedema attacks in a median 1.28 hours, compared with more than 12 hours on placebo.
Lancet publishes a phase 3 on-demand trial against a placebo that took more than 12
The Lancet has published a phase 3 trial of an oral on-demand drug for hereditary angioedema attacks. In RAPIDe-3, a randomised, double-blind, placebo-controlled crossover study, median time to the start of symptom relief was 1.28 hours with deucrictibant and more than 12 hours with placebo. The paper went online on 8 October 2026. Hereditary angioedema causes unpredictable swelling. Unlike allergic swelling, it does not answer to antihistamines, steroids or epinephrine, and an attack in the throat can close the airway. Treatment has largely meant injections. A pill that starts to work in about 77 minutes, in a trial where placebo took half a day, is a practical change if regulators agree. A separate once-daily prophylaxis study of an extended-release form, CHAPTER-3, has reported an 83 percent reduction in monthly attacks versus placebo. That is a different regimen. Today's peer-reviewed news is the on-demand result. This is not the CRISPR one-shot also being tested in this disease. Do not merge the numbers.
Key Facts
- Journal: The Lancet, 8 October 2026
- Trial: RAPIDe-3, phase 3, crossover
- Median time to symptom relief: 1.28 hours versus more than 12 hours on placebo
- Disease does not respond to antihistamines, steroids or epinephrine
- Not an approval announcement
- Sources: The Lancet, HCPLive report of the published trial
Why This Matters
Rare-disease drugs often arrive as infusions in a hospital. An oral on-demand option, if it holds up at the regulator, is the difference between treating an attack at home and waiting on a kit. The placebo gap is large enough to be the story, and large enough that it still needs a second look at who was enrolled.
What We Don't Know Yet
- Not approved on the strength of this publication alone
- Attack-free rates and safety tables need the full paper, not the commentary
- Prophylaxis data are a different trial and should not be quoted as this result